<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>Cerebrovascular diseases can causes <z:hpo ids='HP_0100543'>cognitive impairment</z:hpo> and <z:hpo ids='HP_0000726'>dementia</z:hpo> by loss of neurons and synaptic connections, destruction of axons, and demyelinization </plain></SENT>
<SENT sid="1" pm="."><plain>Biological markers including genetic tests, brain imaging techniques, and biochemical assays in the CSF are valuable for the identification and quantification of cerebrovascular diseases </plain></SENT>
<SENT sid="2" pm="."><plain>Genetic tests may be used to detect mutations that cause hereditary <z:hpo ids='HP_0011970'>cerebral amyloid angiopathies</z:hpo> or cerebral <z:hpo ids='HP_0000006'>autosomal dominant</z:hpo> <z:e sem="disease" ids="C0852949" disease_type="Disease or Syndrome" abbrv="">arteriopathy</z:e> with subcortical <z:mpath ids='MPATH_124'>infarcts</z:mpath> and <z:hpo ids='HP_0002352'>leukoencephalopathy</z:hpo> (CADASIL) </plain></SENT>
<SENT sid="3" pm="."><plain>Structural CT and <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MR</z:e> imaging is routinely used to visualize and quantify <z:mpath ids='MPATH_124'>infarcts</z:mpath> and white-matter changes </plain></SENT>
<SENT sid="4" pm="."><plain>Functional SPET and PET imaging can demonstrate focal and remote effects of vascular lesions on cerebral blood flow and metabolism </plain></SENT>
<SENT sid="5" pm="."><plain>Biochemical imaging using proton MRS is a nonspecific marker for neuronal and axonal damage </plain></SENT>
<SENT sid="6" pm="."><plain>Among biochemical markers in the CSF, tau protein, phospho-tau, and beta amyloid protein are helpful to differentiate vascular <z:hpo ids='HP_0000726'>dementia</z:hpo> from <z:e sem="disease" ids="C0002395" disease_type="Disease or Syndrome" abbrv="SDAT">Alzheimer's disease</z:e> </plain></SENT>
</text></document>